SwePub
Tyck till om SwePub Sök här!
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Morse Michael) "

Sökning: WFRF:(Morse Michael)

  • Resultat 11-12 av 12
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  •  
12.
  • Wolin, Edward M., et al. (författare)
  • Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
  • 2015
  • Ingår i: Drug Design, Development and Therapy. - 1177-8881. ; 9, s. 5075-5086
  • Tidskriftsartikel (refereegranskat)abstract
    • In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide long-acting repeatable (octreotide LAR) in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults with carcinoid tumors of the digestive tract were randomly assigned (1:1) to receive pasireotide LAR (60 mg) or octreotide LAR (40 mg) every 28 days. Primary outcome was symptom control based on frequency of bowel movements and flushing episodes. Objective tumor response was a secondary outcome. Progression-free survival (PFS) was calculated in a post hoc analysis. Adverse events were recorded. At the time of a planned interim analysis, the data monitoring committee recommended halting the study because of a low predictive probability of showing superiority of pasireotide over octreotide for symptom control (n=43 pasireotide LAR, 20.9%; n=45 octreotide LAR, 26.7%; odds ratio, 0.73; 95% confidence interval [CI], 0.27-1.97; P=0.53). Tumor control rate at month 6 was 62.7% with pasireotide and 46.2% with octreotide (odds ratio, 1.96; 95% CI, 0.89-4.32; P=0.09). Median (95% CI) PFS was 11.8 months (11.0 - not reached) with pasireotide versus 6.8 months (5.6 - not reached) with octreotide (hazard ratio, 0.46; 95% CI, 0.20-0.98; P=0.045). The most frequent drug-related adverse events (pasireotide vs octreotide) included hyperglycemia (28.3% vs 5.3%), fatigue (11.3% vs 3.5%), and nausea (9.4% vs 0%). We conclude that, among patients with carcinoid symptoms refractory to available somatostatin analogues, similar proportions of patients receiving pasireotide LAR or octreotide LAR achieved symptom control at month 6. Pasireotide LAR showed a trend toward higher tumor control rate at month 6, although it was statistically not significant, and was associated with a longer PFS than octreotide LAR.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-12 av 12
Typ av publikation
tidskriftsartikel (12)
Typ av innehåll
refereegranskat (11)
övrigt vetenskapligt/konstnärligt (1)
Författare/redaktör
BRYNGEMARK, LENE (1)
Hansen, E. (1)
Bohm, Christian (1)
Dallapiccola, C. (1)
Johns, K. A. (1)
Kolanoski, H. (1)
visa fler...
Mermod, P. (1)
Relich, M. (1)
Richter, R. (1)
Sander, H. G. (1)
Vallecorsa, S. (1)
Koepke, L. (1)
Richter, S. (1)
Christov, A. (1)
Schmitz, M. (1)
Milstead, David A. (1)
Boeser, S. (1)
Bai, X. (1)
Terliuk, A. (1)
Black, John H, 1949 (1)
Gay, P. (1)
Kowalski, M. (1)
Song, M. (1)
Van Eijndhoven, N. (1)
Vallee, C. (1)
Kooijman, P. (1)
De Simone, Andrea (1)
Heinrich, Lukas (1)
Mamuzic, Judita (1)
Morandini, Alessandr ... (1)
Sekmen, Sezen (1)
Pedro, Kevin (1)
Aartsen, M. G. (1)
Abraham, K. (1)
Ackermann, M. (1)
Adams, J. (1)
Aguilar, J. A. (1)
Ahrens, Maryon (1)
Ahrens, M. (1)
Altmann, D. (1)
Anderson, T. (1)
Archinger, M. (1)
Arguelles, C. (1)
Arlen, T. C. (1)
Auffenberg, J. (1)
Barwick, S. W. (1)
Baum, V. (1)
Bay, R. (1)
Beatty, J. J. (1)
Tjus, J. Becker (1)
visa färre...
Lärosäte
Uppsala universitet (4)
Stockholms universitet (4)
Lunds universitet (3)
Göteborgs universitet (1)
Umeå universitet (1)
Kungliga Tekniska Högskolan (1)
visa fler...
Linköpings universitet (1)
Chalmers tekniska högskola (1)
Karolinska Institutet (1)
visa färre...
Språk
Engelska (12)
Forskningsämne (UKÄ/SCB)
Naturvetenskap (7)
Medicin och hälsovetenskap (5)
Teknik (1)
Samhällsvetenskap (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy